Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib-treated Patients with BRAF ^V600-mutated Metastatic Melanoma.

ABSTRACT:

Purpose

Previous investigations identified transcriptional signatures associated with innate resistance to anti-programmed cell death protein 1 therapy in melanoma. This analysis aimed to increase understanding of the role of baseline genetic features in the variability of response to BRAF and MEK inhibitor therapy for BRAF ^V600-mutated metastatic melanoma.

Patients and methods

This exploratory analysis compared genomic features, using whole-exome and RNA sequencing, of baseline tumors from patients who had complete response versus rapid progression (disease progression at first postbaseline assessment) on treatment with cobimetinib combined with vemurafenib or vemurafenib alone. Associations of gene expression with progression-free survival or overall surv

SUBMITTER: Yan Y 

PROVIDER: S-EPMC8083896 | biostudies-literature | 2019 Jun

REPOSITORIES: biostudies-literature